Intellipharmaceutics International Inc
TSX:IPCI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Wacker Chemie AG
XETRA:WCH
|
DE |
|
S
|
Shangri-La Hotels (Malaysia) Bhd
KLSE:SHANG
|
MY |
|
M
|
Misawa & Co Ltd
TSE:3169
|
JP |
|
M
|
MHC JSC
VN:MHC
|
VN |
|
N
|
NZ Automotive Investments Ltd
NZX:NZA
|
NZ |
|
Lundin Energy AB
OTC:LNDNF
|
SE |
|
N
|
Nan Yang Dyeing & Finishing Co Ltd
TWSE:1410
|
TW |
|
HFCL Ltd
NSE:HFCL
|
IN |
|
James Latham PLC
LSE:LTHM
|
UK |
|
GameStop Corp
NYSE:GME
|
US |
|
S
|
Stendorren Fastigheter AB
STO:STEF B
|
SE |
|
Y
|
Yunnan Wenshan Electric Power Co Ltd
SSE:600995
|
CN |
|
Valid Solucoes SA
BOVESPA:VLID3
|
BR |
|
Y
|
Y's Table Corp
TSE:2798
|
JP |
|
R
|
Red Metal Resources Ltd
CNSX:RMES
|
CA |
|
Kama Holdings Ltd
BSE:532468
|
IN |
|
Honda India Power Products Ltd
NSE:HONDAPOWER
|
IN |
|
Care Property Invest NV
XBRU:CPINV
|
BE |
|
Shricon Industries Ltd
BSE:508961
|
IN |
|
GQG Partners Inc
ASX:GQG
|
US |
|
Vedavaag Systems Ltd
BSE:533056
|
IN |
|
Akeso Inc
HKEX:9926
|
CN |
|
Red Electrica Corporacion SA
LSE:0RI5
|
ES |
Intellipharmaceutics International Inc
EPS (Diluted)
Intellipharmaceutics International Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Intellipharmaceutics International Inc
TSX:IPCI
|
EPS (Diluted)
$0
|
CAGR 3-Years
11%
|
CAGR 5-Years
49%
|
CAGR 10-Years
29%
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
EPS (Diluted)
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Canopy Growth Corp
TSX:WEED
|
EPS (Diluted)
CA$0
|
CAGR 3-Years
47%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
EPS (Diluted)
$0
|
CAGR 3-Years
64%
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
EPS (Diluted)
-$1
|
CAGR 3-Years
6%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-6%
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
EPS (Diluted)
CA$0
|
CAGR 3-Years
42%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Intellipharmaceutics International Inc
Glance View
Intellipharmaceutics International, Inc. is a pharmaceutical company, which engages in the research, development, and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The company is headquartered in Etobicoke, Ontario. The firm is specializing in the research, development and manufacture of generic controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. Based on this technology platform, it has developed various drug delivery systems and a pipeline of products and product candidates in various stages of development, in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract (GIT), diabetes and pain. Its Paradoxical OverDose Resistance Activating System (PODRAS) delivery technology is designed to prevent overdose when more pills than prescribed are swallowed intact. Its product and product candidates include Generic Focalin XR, Generic Keppra XR, Generic Glucophage XR and Generic Effexor XR, among others.
See Also
What is Intellipharmaceutics International Inc's EPS (Diluted)?
EPS (Diluted)
-0.1
USD
Based on the financial report for Aug 31, 2023, Intellipharmaceutics International Inc's EPS (Diluted) amounts to -0.1 USD.
What is Intellipharmaceutics International Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
29%
Over the last year, the EPS (Diluted) growth was 17%. The average annual EPS (Diluted) growth rates for Intellipharmaceutics International Inc have been 11% over the past three years , 49% over the past five years , and 29% over the past ten years .
